Acuitas Investments LLC Cuts Position in XOMA Royalty Corporation (NASDAQ:XOMA)

Acuitas Investments LLC decreased its position in XOMA Royalty Corporation (NASDAQ:XOMA - Free Report) by 90.7% during the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 5,674 shares of the biotechnology company's stock after selling 55,030 shares during the period. Acuitas Investments LLC's holdings in XOMA Royalty were worth $113,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the company. Woodline Partners LP grew its holdings in XOMA Royalty by 63.9% in the fourth quarter. Woodline Partners LP now owns 156,266 shares of the biotechnology company's stock valued at $4,107,000 after purchasing an additional 60,927 shares during the last quarter. Eversept Partners LP grew its holdings in XOMA Royalty by 1.2% in the fourth quarter. Eversept Partners LP now owns 95,417 shares of the biotechnology company's stock valued at $2,508,000 after purchasing an additional 1,128 shares during the last quarter. Northern Trust Corp grew its holdings in XOMA Royalty by 1.5% in the fourth quarter. Northern Trust Corp now owns 91,181 shares of the biotechnology company's stock valued at $2,396,000 after purchasing an additional 1,340 shares during the last quarter. Charles Schwab Investment Management Inc. grew its holdings in XOMA Royalty by 5.8% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 23,113 shares of the biotechnology company's stock valued at $607,000 after purchasing an additional 1,276 shares during the last quarter. Finally, Renaissance Technologies LLC grew its holdings in XOMA Royalty by 89.8% in the fourth quarter. Renaissance Technologies LLC now owns 16,100 shares of the biotechnology company's stock valued at $423,000 after purchasing an additional 7,619 shares during the last quarter. Institutional investors and hedge funds own 95.92% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on XOMA. Benchmark began coverage on XOMA Royalty in a research report on Thursday, April 17th. They issued a "buy" rating and a $35.00 price objective on the stock. Wall Street Zen downgraded shares of XOMA Royalty from a "buy" rating to a "hold" rating in a report on Saturday, June 28th. Finally, HC Wainwright reiterated a "buy" rating and set a $104.00 price target on shares of XOMA Royalty in a report on Wednesday, May 28th.

XOMA Royalty Trading Up 1.2%

Shares of NASDAQ XOMA traded up $0.32 during midday trading on Friday, reaching $26.43. 25,289 shares of the stock were exchanged, compared to its average volume of 35,079. The stock has a 50 day moving average price of $25.23 and a 200-day moving average price of $24.24. XOMA Royalty Corporation has a 52-week low of $18.35 and a 52-week high of $35.00. The company has a market capitalization of $316.34 million, a P/E ratio of -22.99 and a beta of 0.93. The company has a current ratio of 5.54, a quick ratio of 5.54 and a debt-to-equity ratio of 1.18.

XOMA Royalty (NASDAQ:XOMA - Get Free Report) last released its earnings results on Tuesday, May 13th. The biotechnology company reported $0.06 earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.32. XOMA Royalty had a negative return on equity of 12.43% and a negative net margin of 13.04%. The firm had revenue of $15.91 million for the quarter, compared to the consensus estimate of $6.75 million. Equities research analysts expect that XOMA Royalty Corporation will post -1.41 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, major shareholder Bvf Partners L. P/Il sold 392,723 shares of the stock in a transaction dated Friday, May 16th. The stock was sold at an average price of $27.10, for a total transaction of $10,642,793.30. Following the transaction, the insider directly owned 1,267,545 shares in the company, valued at approximately $34,350,469.50. This represents a 23.65% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Joseph M. Limber bought 5,243 shares of XOMA Royalty stock in a transaction that occurred on Monday, April 7th. The shares were acquired at an average price of $25.60 per share, for a total transaction of $134,220.80. Following the completion of the transaction, the director directly owned 10,000 shares of the company's stock, valued at $256,000. This trade represents a 110.22% increase in their position. The disclosure for this purchase can be found here. 9.10% of the stock is owned by company insiders.

XOMA Royalty Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.